La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Amedisys Crescita futura

Future criteri di controllo 3/6

Amedisys prevede che gli utili e i ricavi cresceranno rispettivamente di 25.4% e 6.3% all'anno. Si prevede che l'EPS crescerà di 24.7% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 12.5% in 3 anni.

Informazioni chiave

25.4%

Tasso di crescita degli utili

24.7%

Tasso di crescita dell'EPS

Healthcare crescita degli utili	19.4%
Tasso di crescita dei ricavi	6.3%
Rendimento futuro del capitale proprio	12.5%
Copertura analitica	Good
Ultimo aggiornamento	29 Jul 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Sep 04

Amedisys: ROIC, Tangible Book Value Each Softening

Aug 24

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Aug 04

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

Jul 27

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Jul 20

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Jun 04

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

May 05

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Apr 20

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Apr 06

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Feb 20

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

Dec 03

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely

Nov 18

Amedisys (NASDAQ:AMED) Could Easily Take On More Debt

Aug 18

Calculating The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Jul 23

Amedisys: Strategic Contessa Acquisition Underpins The Home Healthcare Growth Opportunity

Jul 18

Under The Bonnet, Amedisys' (NASDAQ:AMED) Returns Look Impressive

Jun 28

It Looks Like Shareholders Would Probably Approve Amedisys, Inc.'s (NASDAQ:AMED) CEO Compensation Package

Jun 02

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

May 24

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:AMED - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	2,677	166	N/A	N/A	3
12/31/2025	2,514	165	177	196	11
12/31/2024	2,354	128	170	176	9
6/30/2024	2,290	92	88	96	N/A
3/31/2024	2,251	-21	91	105	N/A
12/31/2023	2,236	-10	124	137	N/A
9/30/2023	2,228	3	105	118	N/A
6/30/2023	2,229	2	101	114	N/A
3/31/2023	2,234	112	103	111	N/A
12/31/2022	2,223	119	126	133	N/A
9/30/2022	2,220	121	91	98	N/A
6/30/2022	2,216	140	166	173	N/A
3/31/2022	2,222	191	177	184	N/A
12/31/2021	2,214	209	182	189	N/A
9/30/2021	2,206	220	242	250	N/A
6/30/2021	2,196	247	264	271	N/A
3/31/2021	2,117	202	331	337	N/A
12/31/2020	2,072	184	284	289	N/A
9/30/2020	2,021	166	294	298	N/A
6/30/2020	1,972	128	256	263	N/A
3/31/2020	1,980	127	180	188	N/A
12/31/2019	1,956	127	194	202	N/A
9/30/2019	1,889	127	184	191	N/A
6/30/2019	1,812	124	204	212	N/A
3/31/2019	1,731	123	197	203	N/A
12/31/2018	1,663	119	217	223	N/A
9/30/2018	1,626	88	184	192	N/A
6/30/2018	1,583	71	128	133	N/A
3/31/2018	1,546	42	N/A	119	N/A
12/31/2017	1,511	30	N/A	106	N/A
9/30/2017	1,474	43	N/A	102	N/A
6/30/2017	1,456	40	N/A	99	N/A
3/31/2017	1,438	46	N/A	77	N/A
12/31/2016	1,419	37	N/A	62	N/A
9/30/2016	1,391	41	N/A	54	N/A
6/30/2016	1,358	38	N/A	78	N/A
3/31/2016	1,313	38	N/A	106	N/A
12/31/2015	1,266	-3	N/A	108	N/A
9/30/2015	1,230	-7	N/A	92	N/A
6/30/2015	1,204	-7	N/A	87	N/A
3/31/2015	1,193	-10	N/A	-45	N/A
12/31/2014	1,188	13	N/A	-66	N/A
9/30/2014	1,191	-4	N/A	-62	N/A
6/30/2014	1,192	-103	N/A	-59	N/A
3/31/2014	1,203	-109	N/A	64	N/A
12/31/2013	1,233	-93	N/A	102	N/A
9/30/2013	1,278	-191	N/A	109	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di AMED ( 25.4% all'anno) è superiore al tasso di risparmio ( 2.5% ).

Guadagni vs Mercato: Si prevede che gli utili di AMED ( 25.4% all'anno) cresceranno più rapidamente del mercato US ( 15.1% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di AMED cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di AMED ( 6.3% all'anno) crescerà più lentamente rispetto al mercato US ( 8.8% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di AMED ( 6.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che il Return on Equity di AMED sarà basso tra 3 anni ( 12.5 %).

Amedisys Crescita futura

Future criteri di controllo 3/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 54%

Price target decreased by 8.5% to US$98.85

Consensus EPS estimates fall by 16%

Price target decreased to US$126

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Consensus EPS estimates fall by 11%

Recent updates

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Insufficient new directors

President notifies of intention to sell stock

Consensus EPS estimates fall by 54%

Third quarter 2023 earnings: EPS misses analyst expectations

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Investor sentiment improves as stock rises 19%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Price target decreased by 8.5% to US$98.85

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS exceeds analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Chairman & CEO exercised options and sold US$221k worth of stock

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Consensus EPS estimates fall by 16%

Price target decreased to US$126

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Consensus EPS estimates fall by 11%

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Price target decreased to US$145

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Price target decreased to US$160

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Price target decreased to US$174

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

Price target decreased to US$184

Chairman & CEO exercised options and sold US$2.8m worth of stock

Full year 2021 earnings: EPS misses analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

High number of new directors

Investor sentiment improved over the past week

Lead Independent Director recently bought US$141k worth of stock

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?

These 4 Measures Indicate That Amedisys (NASDAQ:AMED) Is Using Debt Safely